Back to home page
HealthValue
Hyperactive B lymphocytes :
- Pathways
- Diseases
- Lifespan and receptors
- Therapies
THERAPIES
Atacicept
Belimumab
Rituximab
& other
anti CD20
monoclonals, see "the anti CD20
monoclonals"
BR3-Fc
- Belimumab is a fully human IgG1 anti BLyS monoclonal. By blocking circulating BLyS it
avoids activation of BCMA, BAFF-R or TACI.
- Atacicept is a recombinant fusion protein built with the extracellular ligand binding portion of TACI. It blocks activation of TACI by APRIL or BLyS.
- BR3-Fc is a recombinant fusion protein built with the extracellular ligand binding portion of BR3. It blocks activation of BAFF-R by BLyS.
- Rituximab and other anti CD20 monoclonals destroy B lymphocytes bearing this antigen.
Abbreviations : APRIL a proliferation inducing ligand; BAFF B cell activation factor of the TNF family (also known as BLyS); BAFF-R receptor for BAFF; Bcl-2 B cell lymphoma gene 2; BCMA B cell maturation antigen; BLyS B lymphocyte stimulator;
BR3 BAFF receptor 3 (also known as BAFF-R); NFk B nuclear factor kappa B; TACI transmembrane activator and calcium modulator and cyclophylin ligand interactor
MONOCLONALS
abatacept
abciximab
adalimumab
alefacept
alemtuzumab
anti KDR
atacicept
basiliximab
belatacept
belimumab
bevacizumab
BR3-Fc
CDP 791
certolizumab
cetuximab
dacluzimab
denosumab
eculizumab
efalizumab
etanercept
IMC 1121
infliximab
ipilimumab
lumiliximab
Mab 806
mapatumumab
matuzumab
natalizumab
nimotuzumab
ocrelizumab
ofatumumab
omalizumab
palivizumab
panitumumab
pertuzumab
ranibizumab
rituximab
ticilimumab
trastuzumab
VEGF Trap
zalutumumab
ABOUT MONOCLONALS
what is a monoclonal
chains & fragments
therapeutic fields
what are CDs
types of monoclonals
fusion proteins
cells to build monoclonals
making monoclonals
IgG1/IgG2 differences
F(ab) fragments
Fc fragment
Fc structure
Fc e receptors
DISEASES
B lymphocyte hyperactivity
bird flu
cancer
diabetes
human growth hormone diseases
lysosomal diseases
mitochondrial diseases
multiple sclerosis
myelodysplastic sd
myopathies
osteoporosis
paroxysmal nocturnal hemoglobinuria
psoriasis
rheumatoid arthritis
BioTherapies
antisense
cell therapy
exon skipping
gene therapy
hemopoietic prog.
monoclonals
protein kinases
recombinant prot.
stem cells
Cells/organelles
B lymphocytes
cell cycle
cells
chromosomes
DNA repair
exons
hemopoietic prog.
introns
lysosomes
mb. receptors
membrane CDs
mitochondria
proteasomes
stem cells
Pathways
Adams
AKT
amino acids
APRIL
BLys
BRCA
complement
cancer pathways
cdk
c-Met
DPP IV
EGF
EGFRvIII
GPCR
G proteins
HGF
ILGF
kinome
Kras
mannose P
MET
mTOR
NFKB
nucleotides
protein kinases
proteins
Ras
RET
sheddases
sunitinib/sorafenib
TACI
TNF
VEGF
Wnt
CD
52
Alemtuzumab
anti CD52
With Belimumab and Atacicept B cell depletion seems less profound and less longlasting than with Rituximab. But this is only a preliminary impression after the June 2007 EULAR (European League Against Rheumatism).
- Alemtuzumab, humanized anti CD52, highly expressed on T & B lymphocytes, was approved in 2001 (FDA) for treatment of chronic lymphocytic leukemia, It shows long lasting activity in multiple sclerosis.